Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Feb;51(2):92–95. doi: 10.1136/jcp.51.2.92

Autografting as first line treatment for chronic myeloid leukaemia.

I O Singer 1, I M Franklin 1
PMCID: PMC500500  PMID: 9602679

Abstract

Interest in autografting for chronic myeloid leukaemia and its clinical relevance has revived in recent years. This followed observations that with various chemotherapeutic regimens it was possible to achieve, temporarily at least, peripheral blood and bone marrow that were Philadelphia negative. Bone marrow or peripheral blood progenitor cells could then be harvested and reinfused following a high dose procedure, hopefully eliminating any residual disease, and resulting in prolonged disease free survival. This ideal has not yet been successfully achieved with current strategies. Recent results indicate that eliminating residual disease with current chemotherapy is not normally achievable. The use of more sensitive technologies such as polymerase chain reaction has revealed persistent disease in most if not all apparently Philadelphia negative cases. This is confirmed by results where disease relapse occurs following transplant in these cases. Despite this, clinically relevant remissions are obtained and further trials are indicated. In this review present treatment is discussed and future strategies, using novel techniques as an adjunct to current treatment, are proposed that might improve on present results or even lead to the elusive goal of cure.

Full text

PDF
92

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan N. C., Richards S. M., Shepherd P. C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995 Jun 3;345(8962):1392–1397. doi: 10.1016/s0140-6736(95)92596-1. [DOI] [PubMed] [Google Scholar]
  2. Apperley J. F., Mauro F. R., Goldman J. M., Gregory W., Arthur C. K., Hows J., Arcese W., Papa G., Mandelli F., Wardle D. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988 Jun;69(2):239–245. doi: 10.1111/j.1365-2141.1988.tb07628.x. [DOI] [PubMed] [Google Scholar]
  3. Bosch G. J., Joosten A. M., Kessler J. H., Melief C. J., Leeksma O. C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996 Nov 1;88(9):3522–3527. [PubMed] [Google Scholar]
  4. Brito-Babapulle F., Bowcock S. J., Marcus R. E., Apperley J., Th'ng K. H., Dowding C., Rassool F., Guo A. P., Catovsky D., Galton D. A. Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol. 1989 Sep;73(1):76–81. doi: 10.1111/j.1365-2141.1989.tb00223.x. [DOI] [PubMed] [Google Scholar]
  5. Butturini A., Keating A., Goldman J., Gale R. P. Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet. 1990 May 26;335(8700):1255–1258. doi: 10.1016/0140-6736(90)91313-y. [DOI] [PubMed] [Google Scholar]
  6. Carella A. M., Chimirri F., Podestà M., Pitto A., Piaggio G., Dejana A., Lerma E., Pollicardo N., Vassallo F., Soracco M. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1996 Feb;17(2):201–205. [PubMed] [Google Scholar]
  7. Carella A. M., Frassoni F., Pollicardo N., Pungolino E., Ferrero R., Vasallo F., Soracco M., Giordano D., Figari O., Benvenuto F. Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 1995 Mar;89(3):535–538. doi: 10.1111/j.1365-2141.1995.tb08360.x. [DOI] [PubMed] [Google Scholar]
  8. Carella A. M., Podestà M., Frassoni F., Pungolino E., Pollicardo N., Raffo M. R., Ferrero R., Benvenuto F., Figari O., Giordano D. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Stem Cells. 1993 Oct;11 (Suppl 3):67–72. doi: 10.1002/stem.5530110917. [DOI] [PubMed] [Google Scholar]
  9. Carella A. M., Pollicardo N., Pungolino E., Raffo M. R., Podesta M., Ferrero R., Pierluigi D., Nati S., Naibo K., Congiu A. Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma. 1993 Apr;9(6):477–483. doi: 10.3109/10428199309145754. [DOI] [PubMed] [Google Scholar]
  10. Chalmers E. A., Franklin I. M., Kelsey S. M., Newland A. C., Clark R. E., Sproul A. M., Crotty G., McCann S. R., Fielding A., Goldstone A. H. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol. 1997 Mar;96(3):627–634. doi: 10.1046/j.1365-2141.1997.d01-2058.x. [DOI] [PubMed] [Google Scholar]
  11. Collins R. H., Jr, Rogers Z. R., Bennett M., Kumar V., Nikein A., Fay J. W. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 1992 Oct;10(4):391–395. [PubMed] [Google Scholar]
  12. Deisseroth A. B., Zu Z., Claxton D., Hanania E. G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson W. F. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15;83(10):3068–3076. [PubMed] [Google Scholar]
  13. Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806–814. doi: 10.7326/0003-4819-108-6-806. [DOI] [PubMed] [Google Scholar]
  14. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994 Mar 24;330(12):820–825. doi: 10.1056/NEJM199403243301204. [DOI] [PubMed] [Google Scholar]
  15. Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1;82(3):691–703. [PubMed] [Google Scholar]
  16. Kolb H. J., Mittermüller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990 Dec 15;76(12):2462–2465. [PubMed] [Google Scholar]
  17. Leemhuis T., Leibowitz D., Cox G., Silver R., Srour E. F., Tricot G., Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 1993 Feb 1;81(3):801–807. [PubMed] [Google Scholar]
  18. McGlave P. B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., Simonsson B., Carella A., Aeppli D. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 1994 Jun 11;343(8911):1486–1488. doi: 10.1016/s0140-6736(94)92589-5. [DOI] [PubMed] [Google Scholar]
  19. O'Brien S. G., Kirkland M. A., Melo J. V., Rao M. H., Davidson R. J., McDonald C., Goldman J. M. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia. 1994 Dec;8(12):2156–2162. [PubMed] [Google Scholar]
  20. Odom L. F., August C. S., Githens J. H., Humbert J. R., Morse H., Peakman D., Sharma B., Rusnak S. L., Johnson F. B. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet. 1978 Sep 9;2(8089):537–540. doi: 10.1016/s0140-6736(78)92879-9. [DOI] [PubMed] [Google Scholar]
  21. Speiser D. E., Tiercy J. M., Rufer N., Grundschober C., Gratwohl A., Chapuis B., Helg C., Löliger C. C., Siren M. K., Roosnek E. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood. 1996 May 15;87(10):4455–4462. [PubMed] [Google Scholar]
  22. Spencer A., O'Brien S. G., Goldman J. M. Options for therapy in chronic myeloid leukaemia. Br J Haematol. 1995 Sep;91(1):2–7. doi: 10.1111/j.1365-2141.1995.tb05236.x. [DOI] [PubMed] [Google Scholar]
  23. Spiers A. S. The treatment of chronic granulocytic leukaemia. Br J Haematol. 1976 Mar;32(3):291–298. doi: 10.1111/j.1365-2141.1976.tb00932.x. [DOI] [PubMed] [Google Scholar]
  24. Szczylik C., Skórski T., Malaguarnera L., Hetman J., Chen S. T., Calabretta B. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem Cytobiol. 1996;34(3-4):129–134. [PubMed] [Google Scholar]
  25. Tari A., Khodadadian M., Ellerson D., Deisseroth A., Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma. 1996 Mar;21(1-2):93–97. doi: 10.3109/10428199609067585. [DOI] [PubMed] [Google Scholar]
  26. Thaler J., Fluckinger T., Huber H., Lang A., Abbrederis C., Seewann H., Silly H., Baldinger C., Duba C., Huber C. Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. Leuk Res. 1993 Aug;17(8):711–715. doi: 10.1016/0145-2126(93)90079-z. [DOI] [PubMed] [Google Scholar]
  27. Thomas E. D., Clift R. A., Fefer A., Appelbaum F. R., Beatty P., Bensinger W. I., Buckner C. D., Cheever M. A., Deeg H. J., Doney K. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986 Feb;104(2):155–163. doi: 10.7326/0003-4819-104-2-155. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES